[20] While specific small-molecule inhibitors of EZH2 are not yet clinically available, there is ongoing interest in the development of such agents. [5] Our SNaPshot-based assay reproducibly detected EZH2 mutations in a substantial proportion of germinal center lymphomas from routine FFPE clinical specimens. The absence of EZH2 mutations in BL highlights both the biological specificity of the EZH2 codon 641 mutation for certain lymphoma subtypes, and the technical specificity of our assay. Here, EZH2 is linked to lymphoma.